Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome injection in second-line small cell lung cancer
CTR20210183Phase 2Completed
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Jan 2021
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in small cell lung cancer (SCLC), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoint: Objective response rate (ORR). Started Jan 2021; status: completed.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20210183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210183.